Antibody-Drug Conjugates
Precision informatics for the next generation of targeted therapeutics.
ADC programs live and die on the interplay of antibody, linker, payload and DAR. We give computational and translational teams analysis-ready datasets and modeling pipelines that de-risk every one of those decisions.
What we do
for your team.
We combine curated conjugate chemistry, PK/PD, and safety datasets with modeling pipelines that quantify DAR distributions, bystander effects, and tumor penetration, so your teams choose linkers, payloads, and antibodies on evidence, not intuition.
Our workflows are engineered for CMC-readiness from day one: harmonized data models, transparent provenance, and IND-ready reporting.
- Antibody sequence, structure & developability analysis
- Payload chemistry libraries and cleavable/non-cleavable linker design
- DAR distribution modeling from LC-MS and HRMS data
- Bystander effect, tumor penetration & PBPK simulations
- Analysis-ready PK, tolerability and safety datasets for ADC benchmarking
- 01
Rationally engineered conjugates with a wider therapeutic index
- 02
Faster CMC readiness through harmonized, traceable data models
- 03
Integrated preclinical dossiers ready for IND-enabling studies